The author has declared a conflict of interest which appears at the end of the article.
Ethical Considerations in Determining Standard of Prevention Packages for HIV Prevention Trials: Examining PrEP
Article first published online: 31 MAY 2013
© 2013 The Authors. Developing World Bioethics published by John Wiley & Sons Ltd.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
Developing World Bioethics
Special Issue: Anti-retrovirals for treatment and prevention – new ethical challenges
Volume 13, Issue 2, pages 87–94, August 2013
How to Cite
Haire, B., Folayan, M. O., Hankins, C., Sugarman, J., McCormack, S., Ramjee, G. and Warren, M. (2013), Ethical Considerations in Determining Standard of Prevention Packages for HIV Prevention Trials: Examining PrEP. Developing World Bioethics, 13: 87–94. doi: 10.1111/dewb.12032
Correction added on 30 April 2014 after original publication: The copyright line and license terms have been amended.
- Issue published online: 18 JUL 2013
- Article first published online: 31 MAY 2013
- National Institute of Allergy and Infectious Disease
- National Institute of Drug Abuse
- National Institute of Mental Health. Grant Number: UM1AI068619
- antiretroviral therapy;
- research ethics;
- developing world bioethics;
- international justice
The successful demonstration that antiretroviral (ARV) drugs can be used in diverse ways to reduce HIV acquisition or transmission risks – either taken as pre-exposure prophylaxis (PrEP) by those who are uninfected or as early treatment for prevention (T4P) by those living with HIV – expands the armamentarium of existing HIV prevention tools. These findings have implications for the design of future HIV prevention research trials. With the advent of multiple effective HIV prevention tools, discussions about the ethics and the feasibility of future HIV prevention trial designs have intensified.
This article outlines arguments concerning the inclusion of newly established ARV-based HIV prevention interventions as standard of prevention in HIV prevention trials from multiple perspectives. Ultimately, there is a clear need to incorporate stakeholders in a robust discussion to determine the appropriate trial design for each study population.